Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluating [18F]FTT PET/CT in Pheochromocytoma and Paraganglioma
NCT05636540Phase 1Recruiting
- Start
- Jul 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of [18F]FluorThanatrace in pheochromocytoma and Paraganglioma (PGL) (2 cohorts). Primary endpoints: Standard uptake value, Maximum standard uptake value and 2 more. Started Jul 2023; status: recruiting.
02
Drugs
[18F]FluorThanatrace
03
Conditions
pheochromocytomaParaganglioma (PGL)
Beyond the preview
Go deeper on NCT05636540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05636540.